KR20140017513A - 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법 - Google Patents

아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법 Download PDF

Info

Publication number
KR20140017513A
KR20140017513A KR1020137016719A KR20137016719A KR20140017513A KR 20140017513 A KR20140017513 A KR 20140017513A KR 1020137016719 A KR1020137016719 A KR 1020137016719A KR 20137016719 A KR20137016719 A KR 20137016719A KR 20140017513 A KR20140017513 A KR 20140017513A
Authority
KR
South Korea
Prior art keywords
seq
ser
antibody
thr
apoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137016719A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 홀츠만
정수 김
홍 지앙
아담 엘토라이
Original Assignee
워싱톤 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워싱톤 유니버시티 filed Critical 워싱톤 유니버시티
Publication of KR20140017513A publication Critical patent/KR20140017513A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020137016719A 2010-12-02 2011-12-02 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법 Withdrawn KR20140017513A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
KR20140017513A true KR20140017513A (ko) 2014-02-11

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137016719A Withdrawn KR20140017513A (ko) 2010-12-02 2011-12-02 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법

Country Status (14)

Country Link
US (2) US20140037638A1 (enExample)
EP (1) EP2646053A4 (enExample)
JP (1) JP2014502276A (enExample)
KR (1) KR20140017513A (enExample)
CN (1) CN103338786A (enExample)
AU (1) AU2011336360A1 (enExample)
BR (1) BR112013013723A2 (enExample)
CA (1) CA2819679A1 (enExample)
MX (1) MX2013006116A (enExample)
NZ (1) NZ611614A (enExample)
RU (1) RU2013130002A (enExample)
SG (1) SG190952A1 (enExample)
WO (1) WO2012075422A2 (enExample)
ZA (1) ZA201303996B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
EP3452074A4 (en) * 2016-05-03 2019-12-11 University of South Florida COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
US11124562B2 (en) 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies
CA3070100A1 (en) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. Antigen binding regions against fibronectin type iii domains and methods of using the same
CN120098122A (zh) * 2019-05-28 2025-06-06 总医院公司 Apoe抗体、融合蛋白及其用途
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
AU2023399623A1 (en) * 2022-11-30 2025-07-03 Bio-Techne Corporation Natural killer cell engagers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951701L (fi) * 1992-10-13 1995-04-10 Univ Duke Menetelmät Alzheimerin taudin tunnistamiseksi
AR047729A1 (es) * 2003-11-28 2006-02-15 Astrazeneca Ab Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
AU2005228764A1 (en) * 2004-03-30 2005-10-13 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
EP1991252A2 (en) * 2006-02-21 2008-11-19 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
AU2007332473B2 (en) * 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
US9102717B2 (en) * 2010-03-01 2015-08-11 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Also Published As

Publication number Publication date
US20160355581A1 (en) 2016-12-08
US20140037638A1 (en) 2014-02-06
CN103338786A (zh) 2013-10-02
WO2012075422A2 (en) 2012-06-07
JP2014502276A (ja) 2014-01-30
WO2012075422A3 (en) 2012-10-04
ZA201303996B (en) 2015-10-28
EP2646053A4 (en) 2014-05-28
NZ611614A (en) 2015-07-31
EP2646053A2 (en) 2013-10-09
CA2819679A1 (en) 2012-06-07
SG190952A1 (en) 2013-07-31
MX2013006116A (es) 2013-10-17
BR112013013723A2 (pt) 2019-09-24
RU2013130002A (ru) 2015-01-10
AU2011336360A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
KR20140017513A (ko) 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법
CN114430744B (zh) 抗Tau抗体及其用途
JP6955721B2 (ja) RGMa結合タンパク質及びその使用
CN1703426B (zh) 识别β-淀粉样肽的人源化抗体
CN106456766B (zh) 抗免疫原性糖肽的抗体、包含其的组合物及其用途
KR100996936B1 (ko) 베타 아밀로이드 펩티드를 인식하는 인간화된 항체
AU2006319358B2 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
CA2761665A1 (fr) Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide
CN111164105B (zh) 抗pacap抗体
JP2009513668A (ja) 線維症、炎症性および新血管形成症状の処置および予防のための組成物および方法
SG185277A1 (en) Humanized antibody
CN104602708A (zh) 痴呆症治疗药或预防药
KR20100097651A (ko) 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도
KR20190109575A (ko) 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
WO2019201133A1 (zh) 神经生长因子的单克隆抗体及其编码基因和应用
US20140127225A1 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
US10556947B2 (en) Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor
WO2016127912A1 (zh) Pcsk9抗体、其药物组合物及其用途
TW202216760A (zh) 抗類澱粉β (ABETA)抗體
CN112513088A (zh) 抗ox40抗体、其抗原结合片段及其医药用途
RU2716101C2 (ru) Антитело к склеростину, его антигенсвязывающий фрагмент и медицинское применение
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
US20220251193A1 (en) Semaphorin 3a antibodies and uses thereof
KR20250004494A (ko) 넥틴-4에 특이적으로 결합하는 단일클론항체 및 이의 용도
CN116688125A (zh) Sema3g抗体在制备抗肿瘤或调节免疫的药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid